Overview

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
OPTIMAS is a large, prospective, partially blinded randomised controlled trial of early (within ≤4 days [96hrs]) or standard (between day 7 and day 14 after stroke onset) initiation of anticoagulation after stroke in patients with atrial fibrillation (AF), using any licensed dose of a direct oral anticoagulant (DOAC). The trial will use a non-inferiority gatekeeper approach to test for non-inferiority of early anticoagulation followed by a test for superiority, if non-inferiority is established.
Phase:
N/A
Details
Lead Sponsor:
University College, London
Treatments:
Anticoagulants
Apixaban
Dabigatran
Edoxaban
Rivaroxaban